Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MYGN's Cash to Debt is ranked higher than
89% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. MYGN: No Debt )
MYGN' s 10-Year Cash to Debt Range
Min: 16.5   Max: No Debt
Current: No Debt

Equity to Asset 0.86
MYGN's Equity to Asset is ranked higher than
92% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. MYGN: 0.86 )
MYGN' s 10-Year Equity to Asset Range
Min: 0.71   Max: 0.96
Current: 0.86

0.71
0.96
Interest Coverage No Debt
MYGN's Interest Coverage is ranked higher than
83% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 261.43 vs. MYGN: No Debt )
MYGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 14.88
M-Score: -2.56
WACC vs ROIC
3.17%
17.81%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 20.95
MYGN's Operating margin (%) is ranked higher than
96% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. MYGN: 20.95 )
MYGN' s 10-Year Operating margin (%) Range
Min: -82.24   Max: 39.24
Current: 20.95

-82.24
39.24
Net-margin (%) 13.17
MYGN's Net-margin (%) is ranked higher than
94% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. MYGN: 13.17 )
MYGN' s 10-Year Net-margin (%) Range
Min: -71.71   Max: 42
Current: 13.17

-71.71
42
ROE (%) 13.52
MYGN's ROE (%) is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.59 vs. MYGN: 13.52 )
MYGN' s 10-Year ROE (%) Range
Min: -25.88   Max: 30.71
Current: 13.52

-25.88
30.71
ROA (%) 11.86
MYGN's ROA (%) is ranked higher than
94% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. MYGN: 11.86 )
MYGN' s 10-Year ROA (%) Range
Min: -23.02   Max: 28.73
Current: 11.86

-23.02
28.73
ROC (Joel Greenblatt) (%) 122.09
MYGN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 300 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. MYGN: 122.09 )
MYGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -238.09   Max: 362.64
Current: 122.09

-238.09
362.64
Revenue Growth (3Y)(%) 31.50
MYGN's Revenue Growth (3Y)(%) is ranked higher than
96% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. MYGN: 31.50 )
MYGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.7   Max: 31.5
Current: 31.5

1.7
31.5
EBITDA Growth (3Y)(%) 27.00
MYGN's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. MYGN: 27.00 )
MYGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.6   Max: 47.2
Current: 27

-10.6
47.2
EPS Growth (3Y)(%) 26.90
MYGN's EPS Growth (3Y)(%) is ranked higher than
93% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. MYGN: 26.90 )
MYGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -16.6   Max: 66.6
Current: 26.9

-16.6
66.6
» MYGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MYGN Guru Trades in Q2 2014

John Burbank 16,676 sh (New)
Andreas Halvorsen 1,330,294 sh (New)
Paul Tudor Jones 12,833 sh (+85.85%)
First Pacific Advisors 251,100 sh (unchged)
John Griffin Sold Out
First Eagle Investment Sold Out
Louis Moore Bacon Sold Out
Chuck Royce 9,299,478 sh (-1.44%)
Joel Greenblatt 1,117,351 sh (-7.36%)
Chase Coleman 1,900,000 sh (-19.01%)
Jim Simons 49,200 sh (-21.66%)
Richard Snow 1,091,227 sh (-39.96%)
» More
Q3 2014

MYGN Guru Trades in Q3 2014

Jim Simons 60,474 sh (+22.91%)
Chase Coleman 1,900,000 sh (unchged)
First Pacific Advisors 251,100 sh (unchged)
John Burbank Sold Out
Andreas Halvorsen Sold Out
Richard Snow 1,055,014 sh (-3.32%)
Chuck Royce 8,906,065 sh (-4.23%)
Joel Greenblatt 869,531 sh (-22.18%)
Paul Tudor Jones 7,976 sh (-37.85%)
» More
Q4 2014

MYGN Guru Trades in Q4 2014

Steven Cohen 360,300 sh (New)
Ken Fisher 88,333 sh (New)
Jim Simons 94,000 sh (+55.44%)
First Pacific Advisors 251,100 sh (unchged)
Chase Coleman 1,900,000 sh (unchged)
Chuck Royce 5,900,143 sh (unchged)
Chuck Royce 5,900,143 sh (unchged)
Chuck Royce 5,084,563 sh (-13.82%)
Paul Tudor Jones 6,518 sh (-18.28%)
Richard Snow 827,803 sh (-21.54%)
Joel Greenblatt 568,865 sh (-34.58%)
Chuck Royce 5,084,563 sh (-42.91%)
» More
Q1 2015

MYGN Guru Trades in Q1 2015

Mario Gabelli 25,000 sh (New)
Louis Moore Bacon 20,795 sh (New)
Jim Simons 273,700 sh (+191.17%)
First Pacific Advisors 251,100 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Richard Snow Sold Out
Ken Fisher 88,050 sh (-0.32%)
Chuck Royce 3,404,200 sh (-33.05%)
Steven Cohen 153,400 sh (-57.42%)
Chase Coleman 291,097 sh (-84.68%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Myriad Genetics Inc

Chuck Royce Comments on Myriad Genetics - Oct 08, 2014

Six equity sectors made net contributions to first-half returns, with Health Care out in front, driven in large part by the terrific results for molecular diagnostic company Myriad Genetics (MYGN), which was among the portfolio’s five largest detractors in 2013 when we substantially increased our position. The company specializes in genetic testing for cancer and ended last year facing increased competition, particularly in breast cancer screening tests, and some still unresolved reimbursement issues that remained under federal review at the end of December. It was also facing skepticism from some quarters about the fallout from a June 2013 Supreme Court decision that genes could not be patented. Our take was that neither the high court ruling nor the increased competition would hurt the firm’s long-term health. We see the quality of its predictive tests as the industry’s gold standard, so we were quite pleased to see it continue to execute successfully (and profitably), as well as make a savvy acquisition of Crescendo Bioscience, in the first half. The acquisition diversifies Myriad’s already promising pipeline. It was the Fund’s largest holding at the end of June.

From Chuck Royce (Trades, Portfolio)’s Royce Premier Fund Second Quarter 2014 Manager Commentary.

Check out Chuck Royce latest stock trades

Baron Funds Comments on Myriad Genetics Inc. - Jun 06, 2013

Myriad Genetics, Inc. (MYGN)develops, markets and performs novel genetic tests in its own proprietary labs. It has a lab in Utah and recently opened a second facility in Munich, Germany to process international tests (a big opportunity as nearly all of current revenues are from U.S. customers). MYGN performed about 150,000 tests in 2012 for breast, colon and skin cancers. The company has 193 issued patents, as well as numerous patent applications in the U.S. and foreign countries. It also has numerous trade secrets (including a one-of-a-kind breast cancer genetic mutation database), which are likely even more important than the patents. We believe that MYGN has the ability to grow revenues by expanding its current test menu as well as growing its European operations and introducing new tests (prostate cancer and companion diagnostics for pharmaceutical usage). (Randy Gwirtzman)

From Baron Funds’ first quarter 2013 commentary.


Check out Ron Baron latest stock trades

Top Ranked Articles about Myriad Genetics Inc

Chuck Royce Comments on Myriad Genetics
Six equity sectors made net contributions to first-half returns, with Health Care out in front, driven in large part by the terrific results for molecular diagnostic company Myriad Genetics (MYGN), which was among the portfolio’s five largest detractors in 2013 when we substantially increased our position. The company specializes in genetic testing for cancer and ended last year facing increased competition, particularly in breast cancer screening tests, and some still unresolved reimbursement issues that remained under federal review at the end of December. It was also facing skepticism from some quarters about the fallout from a June 2013 Supreme Court decision that genes could not be patented. Our take was that neither the high court ruling nor the increased competition would hurt the firm’s long-term health. We see the quality of its predictive tests as the industry’s gold standard, so we were quite pleased to see it continue to execute successfully (and profitably), as well as make a savvy acquisition of Crescendo Bioscience, in the first half. The acquisition diversifies Myriad’s already promising pipeline. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.60
MYGN's P/E(ttm) is ranked higher than
90% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 27.60 )
MYGN' s 10-Year P/E(ttm) Range
Min: 9.09   Max: 80.49
Current: 27.6

9.09
80.49
Forward P/E 18.66
MYGN's Forward P/E is ranked higher than
88% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 18.66 )
N/A
PE(NRI) 27.70
MYGN's PE(NRI) is ranked higher than
92% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 27.70 )
MYGN' s 10-Year PE(NRI) Range
Min: 9.1   Max: 81.3
Current: 27.7

9.1
81.3
P/B 3.82
MYGN's P/B is ranked higher than
65% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. MYGN: 3.82 )
MYGN' s 10-Year P/B Range
Min: 1.89   Max: 8.23
Current: 3.82

1.89
8.23
P/S 3.63
MYGN's P/S is ranked higher than
57% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. MYGN: 3.63 )
MYGN' s 10-Year P/S Range
Min: 2.32   Max: 14.79
Current: 3.63

2.32
14.79
PFCF 25.26
MYGN's PFCF is ranked higher than
88% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 25.26 )
MYGN' s 10-Year PFCF Range
Min: 7.63   Max: 140.77
Current: 25.26

7.63
140.77
POCF 20.12
MYGN's POCF is ranked higher than
87% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 20.12 )
MYGN' s 10-Year POCF Range
Min: 7.21   Max: 43.85
Current: 20.12

7.21
43.85
EV-to-EBIT 15.00
MYGN's EV-to-EBIT is ranked higher than
93% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 15.00 )
MYGN' s 10-Year EV-to-EBIT Range
Min: -102.6   Max: 52.4
Current: 15

-102.6
52.4
PEG 1.22
MYGN's PEG is ranked higher than
98% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 1.22 )
MYGN' s 10-Year PEG Range
Min: 0.43   Max: 1.57
Current: 1.22

0.43
1.57
Shiller P/E 22.12
MYGN's Shiller P/E is ranked higher than
93% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 22.12 )
MYGN' s 10-Year Shiller P/E Range
Min: 14.52   Max: 502.6
Current: 22.12

14.52
502.6
Current Ratio 4.20
MYGN's Current Ratio is ranked higher than
83% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. MYGN: 4.20 )
MYGN' s 10-Year Current Ratio Range
Min: 2.2   Max: 20.28
Current: 4.2

2.2
20.28
Quick Ratio 3.77
MYGN's Quick Ratio is ranked higher than
83% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. MYGN: 3.77 )
MYGN' s 10-Year Quick Ratio Range
Min: 2.2   Max: 20.28
Current: 3.77

2.2
20.28
Days Inventory 61.08
MYGN's Days Inventory is ranked higher than
81% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. MYGN: 61.08 )
MYGN' s 10-Year Days Inventory Range
Min: 22.14   Max: 48.67
Current: 61.08

22.14
48.67
Days Sales Outstanding 46.61
MYGN's Days Sales Outstanding is ranked higher than
87% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.63 vs. MYGN: 46.61 )
MYGN' s 10-Year Days Sales Outstanding Range
Min: 9.44   Max: 90.17
Current: 46.61

9.44
90.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 104.85
MYGN's Price/Net Cash is ranked higher than
75% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 104.85 )
MYGN' s 10-Year Price/Net Cash Range
Min: 2.9   Max: 107.27
Current: 104.85

2.9
107.27
Price/Net Current Asset Value 14.85
MYGN's Price/Net Current Asset Value is ranked higher than
74% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 14.85 )
MYGN' s 10-Year Price/Net Current Asset Value Range
Min: 2.41   Max: 27.64
Current: 14.85

2.41
27.64
Price/Tangible Book 8.87
MYGN's Price/Tangible Book is ranked higher than
64% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.20 vs. MYGN: 8.87 )
MYGN' s 10-Year Price/Tangible Book Range
Min: 1.53   Max: 18.98
Current: 8.87

1.53
18.98
Price/DCF (Projected) 1.01
MYGN's Price/DCF (Projected) is ranked higher than
95% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 1.01 )
MYGN' s 10-Year Price/DCF (Projected) Range
Min: 0.64   Max: 22.85
Current: 1.01

0.64
22.85
Price/Median PS Value 0.58
MYGN's Price/Median PS Value is ranked higher than
94% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. MYGN: 0.58 )
MYGN' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 7.26
Current: 0.58

0.36
7.26
Price/Peter Lynch Fair Value 1.47
MYGN's Price/Peter Lynch Fair Value is ranked higher than
100% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 1.47 )
MYGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.43   Max: 1.7
Current: 1.47

0.43
1.7
Price/Graham Number 3.25
MYGN's Price/Graham Number is ranked higher than
87% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 3.25 )
MYGN' s 10-Year Price/Graham Number Range
Min: 0.97   Max: 3.33
Current: 3.25

0.97
3.33
Earnings Yield (Greenblatt) 6.70
MYGN's Earnings Yield (Greenblatt) is ranked higher than
93% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. MYGN: 6.70 )
MYGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.9   Max: 22.7
Current: 6.7

1.9
22.7
Forward Rate of Return (Yacktman) 23.79
MYGN's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. MYGN: 23.79 )
MYGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.9   Max: 33.1
Current: 23.79

-19.9
33.1

Analyst Estimate

Jun15 Jun16 Jun17
Revenue(Mil) 725 771 792
EPS($) 1.43 1.85 1.96
EPS without NRI($) 1.43 1.85 1.96

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:MYD.Germany,
Myriad Genetics Inc is a molecular diagnostic company, engaged in making a difference in patients lives through the discovery and commercialization of transformative tests which assess a persons risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. The Companys business segments include: research, molecular diagnostics and companion diagnostics. The research segment is engaged in the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to ensure optimal treatment, or assess a patients risk of disease progression and disease recurrence. The companion diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company offers nine commercial molecular diagnostic tests, including six predictive medicine tests, two personalized medicine tests, and one prognostic medicine test. The Company markets these tests through its sales force of approximately 400 people in the United States. It also markets BRACAnalysis, COLARIS, COLARIS AP, and Prolaris tests through its European sales force. The Companys competitors include other molecular diagnostic companies, diagnostic reference laboratories, large multi-national healthcare companies, and universities and other research institutions. The Company has 234 patents as well as patent applications in the United States and foreign countries. The patents and patent applications cover diagnostic biomarkers, genes, proteins, gene expression signatures, antibodies, primers, probes, assays, disease-associated genetic mutations and single-nucleotide polymorphisms, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for correlation claims, and methods for disease treatment, and general molecular diagnostic techniques. The Companys U.S. patents relating to BRACAnalysis, COLARIS, COLARIS AP, MELARIS, PREZEON, PANEXIA and TruCulture also have related foreign issued patents in countries, including in Europe, Canada, Japan, Australia and New Zealand, claiming similar subject matter and having similar expiration dates. The services that the Company provides are regulated by federal, state and foreign governmental authorities.
» More Articles for MYGN

Headlines

Articles On GuruFocus.com
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 
Myriad Genetics Inc. (MYGN) CFO James S Evans sells 8,400 Shares Mar 12 2010 

More From Other Websites
Myriad Validates Active Surveillance Threshold With Prolaris(R) for Men With Prostate Cancer May 15 2015
Myriad Validates Active Surveillance Threshold With Prolaris(R) for Men With Prostate Cancer May 15 2015
Myriad Showcases Its Pioneering Research at the 2015 ASCO Annual Meeting May 13 2015
Myriad Showcases Its Pioneering Research at the 2015 ASCO Annual Meeting May 13 2015
Myriad Genetics Q3 Test Growth Impresses Yet Revenues Fall - Analyst Blog May 11 2015
10-Q for Myriad Genetics, Inc. May 08 2015
Myriad to Present New Clinical Data on Prolaris(R) at the AUA 2015 Annual Meeting May 07 2015
Myriad to Present New Clinical Data on Prolaris(R) at the AUA 2015 Annual Meeting May 07 2015
Myriad Genetics Posts In-Line Q3 Earnings, Guides Lower - Analyst Blog May 06 2015
MYRIAD GENETICS INC Files SEC form 10-Q, Quarterly Report May 06 2015
Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results May 05 2015
Myriad meets 3Q profit forecasts May 05 2015
Myriad meets 3Q profit forecasts May 05 2015
Myriad Genetics Inc Earnings Call scheduled for 4:30 pm ET today May 05 2015
MYRIAD GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 05 2015
Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results May 05 2015
Q3 2015 Myriad Genetics Inc Earnings Release - After Market Close May 05 2015
PDF 11.91 KB May 04 2015
Myriad Genetics Fights Off Threats From Rivals May 03 2015
11 Buyout Targets Credit Suisse Is Watching Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK